LORAZEPAM DIN 02429802
Health Canada record
| Active ingredient(s) | LORAZEPAM 0.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| Class | Human |
| ATC | N05BA06 LORAZEPAM |
| Original market date | |
| Current status date | 03-Jul-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sivem Pharmaceuticals ULC — licence 101965, currently licensed, last inspection rating C (2025-02-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LORAZEPAM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00655740 | APO-LORAZEPAM | APOTEX INC | Tablet | LORAZEPAM 0.5 MG | Marketed |
| 00655767 | APO-LORAZEPAM | APOTEX INC | Tablet | LORAZEPAM 2 MG | Marketed |
| 00655759 | APO-LORAZEPAM | APOTEX INC | Tablet | LORAZEPAM 1 MG | Marketed |
| 02564297 | AURO-LORAZEPAM | AURO PHARMA INC | Tablet | LORAZEPAM 2 MG | Approved |
| 02564300 | AURO-LORAZEPAM | AURO PHARMA INC | Tablet | LORAZEPAM 1 MG | Approved |
| 02564319 | AURO-LORAZEPAM | AURO PHARMA INC | Tablet | LORAZEPAM 0.5 MG | Approved |
| 02243278 | LORAZEPAM INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | LORAZEPAM 4 MG | Marketed |
| 02550962 | LORAZEPAM INJECTION, USP | FRESENIUS KABI CANADA LTD | Solution | LORAZEPAM 4 MG | Marketed |
| 02410753 | LORAZEPAM SUBLINGUAL | AA PHARMA INC | Tablet | LORAZEPAM 1 MG | Marketed |
| 02410761 | LORAZEPAM SUBLINGUAL | AA PHARMA INC | Tablet | LORAZEPAM 2 MG | Marketed |
| 02410745 | LORAZEPAM SUBLINGUAL | AA PHARMA INC | Tablet | LORAZEPAM 0.5 MG | Marketed |
| 00728187 | PMS-LORAZEPAM | PHARMASCIENCE INC | Tablet | LORAZEPAM 0.5 MG | Marketed |
| 00728209 | PMS-LORAZEPAM | PHARMASCIENCE INC | Tablet | LORAZEPAM 2 MG | Marketed |
| 00728195 | PMS-LORAZEPAM | PHARMASCIENCE INC | Tablet | LORAZEPAM 1 MG | Marketed |
| 00655643 | PRO-LORAZEPAM | PRO DOC LIMITEE | Tablet | LORAZEPAM 0.5 MG | Marketed |
| 00655678 | PRO-LORAZEPAM | PRO DOC LIMITEE | Tablet | LORAZEPAM 2 MG | Marketed |
| 00655651 | PRO-LORAZEPAM | PRO DOC LIMITEE | Tablet | LORAZEPAM 1 MG | Marketed |
| 00637750 | TEVA-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 2 MG | Marketed |
| 00637742 | TEVA-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 1 MG | Marketed |
| 00711101 | TEVA-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 0.5 MG | Marketed |
| 02041413 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 02041421 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02041448 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02041456 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 02041464 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02041472 | ATIVAN | PFIZER CANADA ULC | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 00557773 | ATIVAN INJ 4MG/ML | WYETH LTD. | Liquid | LORAZEPAM 4 MG | Cancelled Post Market |
| 02041405 | ATIVAN INJECTION LIQ 4MG/ML | WYETH CANADA | Solution | LORAZEPAM 4 MG | Cancelled Post Market |
| 00722138 | ATIVAN SUBL TAB 0.5MG | WYETH LTD. | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 00557757 | ATIVAN SUBL TAB 1MG | WYETH LTD. | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 00348325 | ATIVAN TAB 1MG | WYETH LTD. | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 00348333 | ATIVAN TAB 2MG | WYETH LTD. | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02245785 | DOM-LORAZEPAM | DOMINION PHARMACAL | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02245786 | DOM-LORAZEPAM | DOMINION PHARMACAL | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02429810 | LORAZEPAM | SIVEM PHARMACEUTICALS ULC | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02351072 | LORAZEPAM | SANIS HEALTH INC | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 02351080 | LORAZEPAM | SANIS HEALTH INC | Tablet | LORAZEPAM 1.0 MG | Cancelled Post Market |
| 02351099 | LORAZEPAM | SANIS HEALTH INC | Tablet | LORAZEPAM 2.0 MG | Cancelled Post Market |
| 02429829 | LORAZEPAM | SIVEM PHARMACEUTICALS ULC | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02388669 | LORAZEPAM INJECTION USP | PFIZER CANADA ULC | Solution | LORAZEPAM 4 MG | Cancelled Post Market |
| 02438704 | LORAZEPAM INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | LORAZEPAM 2 MG | Cancelled Post Market |
| 02347768 | NTP-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 2.0 MG | Cancelled Pre Market |
| 02347733 | NTP-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 0.5 MG | Cancelled Pre Market |
| 02347741 | NTP-LORAZEPAM | TEVA CANADA LIMITED | Tablet | LORAZEPAM 1.0 MG | Cancelled Pre Market |
| 00865680 | NU-LORAZ TAB 1MG | NU-PHARM INC | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 00865699 | NU-LORAZ TAB 2MG | NU-PHARM INC | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02298201 | PHL-LORAZEPAM | PHARMEL INC | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 02298236 | PHL-LORAZEPAM | PHARMEL INC | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
| 02298228 | PHL-LORAZEPAM | PHARMEL INC | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02240725 | RIVA-LORAZEPAM 0.5 MG TABLETS | LABORATOIRE RIVA INC. | Tablet | LORAZEPAM 0.5 MG | Cancelled Post Market |
| 02240726 | RIVA-LORAZEPAM 1 MG TABLETS | LABORATOIRE RIVA INC. | Tablet | LORAZEPAM 1 MG | Cancelled Post Market |
| 02240727 | RIVA-LORAZEPAM 2MG TABLETS | LABORATOIRE RIVA INC. | Tablet | LORAZEPAM 2 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16010 | 2014-08-28 | New Drug Submission (NDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for LORAZEPAM
5 valid EDQM Certificates of Suitability from 5 holders. 8 active FDA Drug Master Files.
Request a quote for LORAZEPAM